These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38656386)

  • 1. Diagnostic interobserver agreement for thyroid fine-needle aspirates: Effects of reviewer experience and molecular diagnostics.
    Gokozan HN; Mostyka M; Scognamiglio T; Solomon JP; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
    Am J Clin Pathol; 2024 Sep; 162(3):302-313. PubMed ID: 38656386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
    Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
    Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Combined Use of Fine-Needle Aspiration (FNA) and BRAF V600E Gene Testing: Can it Increase the Definitive Diagnosis Rate of Nodules Categorized as Bethesda III for Papillary Thyroid Carcinoma?
    Lei L; Hong Qing S; Wei L; Ma Mo Yang F; Xiao Xiang Y
    Am Surg; 2024 Dec; 90(12):3209-3215. PubMed ID: 39047144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
    Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J; Ahn S; Shin JH; Oh YL
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating local thyroid cytopathology practices by molecular quality metrics: A multi-institutional study on 4651 FNAs with a focus on the role of the interventional cytopathologist.
    Nacchio M; Palladino R; Vigliar E; Pisapia P; Salatiello M; Malapelle U; Porcelli T; Luongo C; Fonderico F; Masone S; Salvatore D; Troncone G; Bellevicine C
    Cancer Cytopathol; 2023 Dec; 131(12):772-780. PubMed ID: 37635646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An institutional experience: A retrospective analysis of the effect of transitioning from follicular lesion of undetermined significance to atypia of undetermined significance with subclassified atypia on interobserver concordance, rates of neoplasia, and rates of malignancy.
    Kroll-Wheeler L; Cantley R; Pang JC; Soles BS; Smola B; Jing X; Lew M
    Diagn Cytopathol; 2021 Jan; 49(1):31-38. PubMed ID: 32936526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation and the Bethesda System for Reporting Thyroid Cytopathology of fine-needle aspiration biopsy for distinguishing benign from malignant thyroid nodules.
    Sheng D; Yu X; Li H; Zhang M; Chen J
    Medicine (Baltimore); 2021 Sep; 100(37):e27167. PubMed ID: 34664843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life utility of five-gene panel test in preoperative thyroid fine-needle aspiration biopsy: a large cohort of 740 patients study.
    Tang J; Ma J; Xi X; Wang L; Li H; Huo S; Zhang B
    Endocrine; 2023 Jun; 80(3):552-562. PubMed ID: 36542267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Value and Challenges of BRAF V600E Molecular Testing and Thyroid Fine-Needle Aspiration Cytology: A Retrospective Study from a Tertiary Institution in Southern Hunan Province, China.
    Lan Z; Yang F; Zhang J; Lan Y; Li H; He R
    Acta Cytol; 2023; 67(6):629-638. PubMed ID: 37708867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid fine-needle aspirations: A six-year institutional experience.
    Xu XM; Angelova E; Clement CG
    Diagn Cytopathol; 2021 Aug; 49(8):915-920. PubMed ID: 33973739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations: Follow-Up and Outcome Experience in Newfoundland, Canada.
    Erivwo P; Ghosh C
    Acta Cytol; 2018; 62(2):85-92. PubMed ID: 29486467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic Value of American Thyroid Association Guidelines,American College of Radiology Thyroid Imaging Reporting and Data System,and Chinese Thyroid Imaging Reporting and Data System Alone and Combined With BRAF
    Lin Y; Luo YK; Li J; Ren XY; Wang HW
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):921-928. PubMed ID: 38173102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.
    Bellevicine C; Migliatico I; Sgariglia R; Nacchio M; Vigliar E; Pisapia P; Iaccarino A; Bruzzese D; Fonderico F; Salvatore D; Biondi B; Masone S; Novizio V; Scavuzzo F; Serino D; De Palma M; Chiofalo MG; Botti G; Pezzullo L; Nuzzo V; Spiezia S; De Chiara G; Iorio S; Conzo G; Docimo G; Faggiano A; Bongiovanni M; Malapelle U; Colao A; Triassi M; Troncone G;
    Cancer Cytopathol; 2020 Feb; 128(2):107-118. PubMed ID: 31821746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Clinical Usefulness of BRAFV600E Mutation Analysis of Core-Needle Biopsy Specimens in Thyroid Nodules with Previous Atypia of Undetermined Significance or Follicular Lesions of Undetermined Significance Results.
    Choi SH; Baek JH; Lee JH; Choi YJ; Song DE; Chung KW; Kim TY; Shong YK
    Thyroid; 2015 Aug; 25(8):897-903. PubMed ID: 25978151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF
    Chen H; Song A; Wang Y; He Y; Tong J; Di J; Li C; Zhou Z; Cai X; Zhong D; Da J
    Cancer Med; 2022 Jan; 11(1):40-49. PubMed ID: 34851044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone Between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More.
    Bagıs M; Can N; Sut N; Tastekin E; Erdogan EG; Bulbul BY; Sezer YA; Kula O; Demirtas EM; Usta I
    Endocr Pathol; 2024 Mar; 35(1):51-76. PubMed ID: 38280141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
    Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
    Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.